Nephros (NASDAQ:NEPH) Stock Price Down 2.8% – Should You Sell?

Nephros, Inc. (NASDAQ:NEPHGet Free Report)’s share price dropped 2.8% during mid-day trading on Monday . The stock traded as low as $1.60 and last traded at $1.60. Approximately 5,861 shares traded hands during mid-day trading, a decline of 22% from the average daily volume of 7,553 shares. The stock had previously closed at $1.65.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and set a $5.00 price target on shares of Nephros in a research note on Tuesday, November 12th.

Read Our Latest Report on NEPH

Nephros Stock Performance

The business has a 50-day moving average of $1.55 and a 200-day moving average of $1.72. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -17.78 and a beta of 1.19.

Hedge Funds Weigh In On Nephros

An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP purchased a new position in shares of Nephros, Inc. (NASDAQ:NEPHFree Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned 0.17% of Nephros at the end of the most recent reporting period. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.